Covalent kinase inhibitor, preparation method, pharmaceutical composition and application
By designing NO/NO2-release covalent warhead kinase inhibitors, the release of NO/NO2-in-availability of NO/NO2 in a very small range using covalent binding and addition-elimination reactions is solved in the prior art. The problem of low results enables efficient targeted inhibition and collaborative treatment effects.
Patent Information
- Application Number
- CN202310642022.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-01
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2043-06-01
AI Technical Summary
The existing NO/NO2-donor drugs and covalent inhibitors have problems such as low release specificity, poor accuracy, low bioavailability, high dosage, large doses, and target Cys mutation resistance, and lack effective synergistic treatment. mechanism.
A kinase inhibitor based on NO/NO2-release covalent warhead was designed, through O2-(α-methylene-α,β-unsaturated ketone)-azonium diol or α-nitromethyl -α,β-unsaturated ketone warhead structure, uses covalent binding and addition-elimination reaction to release NO/NO2- in a very small range, achieving selective and targeted release, and combining the synergistic effect of NO/NO2- to Enhance the efficacy of the medicine.
It improves the specificity and accuracy of NO/NO2-release, reduces non-target inhibition, reduces drug dosage, improves biological activity and safety, and significantly inhibits the growth of enzymes and tumors related to malignant proliferation.
Smart Images

Figure CN119060055A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a method based on NO / NO2 — Kinase inhibitors of release-type covalent warheads, preparation methods, pharmaceutical compositions and applications, particularly a NO / NO2-based kinase inhibitor with synergistic effects — Kinase inhibitors with releasable covalent warheads, preparation methods, pharmaceutical compositions and applications. Background Art
[0002] NO is a water-soluble free radical gas in organisms with redox properties. It plays an important role in physiology and pathology. It plays an extremely important biological role in cardiovascular and cerebrovascular regulation, nerve and immune regulation. — It is one of the metabolites of NO in the body. It can be reduced to NO under ischemic and hypoxic conditions. In some cases, it can also be regarded as a type of NO donor. NO can react with protein cysteine sulfhydryl groups to mediate protein cysteine sulfhydryl nitrosylation (SNO), which is a very important post-translational modification. It is worth mentioning that SNO can also be converted from NO2 — Mediated occurrence.
[0003] NO / NO2 — Donor drugs generally refer to those composed of NO / NO2 — A prodrug formed by a donor and a related drug or an active compound through various connecting groups. Various structural types of NO donors have been discovered, such as nitrosothiol, nitrate, NO-metal complex (nitroprusside), furazan N-oxide, azodiol salt, etc.; NO2 — The donor includes 2-nitromethyl-1,3-diphenyl-2-en-1-one and the like.
[0004] Covalent kinase inhibitors irreversibly bind to target kinase residues (generally Cys) through covalent bonds, thereby exerting target inhibition function and achieving the purpose of disease treatment. They generally contain a less reactive bonding functional group (warhead group) and a ligand part. After the ligand locates the inhibitor at the corresponding site of the target kinase, the warhead group reacts with Cys to form a covalent bond.
[0005] Although NO / NO2 — Donor drugs and covalent inhibitors have experienced great development, but still face many shortcomings. For example, for NO / NO2 — For donor drugs, they trigger NO / NO2 — The release mechanism currently relies on chemical and biological methods such as light control and sound control; NO / NO2 — The specificity and accuracy of the released NO / NO2 are low. —Due to its free diffusion nature, the target at the molecular level is uncertain. — It will act on multiple biological macromolecules and produce more side effects. — Donor drugs still need to explore NO / NO2 with higher specificity and better accuracy — Release mode.
[0006] For covalent inhibitors, although they have a high target occupancy rate, this also leads to a single mode of action and a lack of effective synergistic treatment mechanism. In addition, existing covalent inhibitors also face the disadvantages of low bioavailability, high frequency of administration, large dosage, and easy to produce target Cys mutation resistance. Therefore, for covalent inhibitors, exploring new synergistic mechanisms may help enhance the efficacy and overcome the above shortcomings to a certain extent. Summary of the invention
[0007] Purpose of the invention: The first purpose of the present invention is to provide a NO / NO2 — The invention relates to a kinase inhibitor with a release-type covalent warhead; the second purpose is to provide a method for preparing the covalent kinase inhibitor; the third purpose is to provide a pharmaceutical composition containing the covalent kinase inhibitor; and the fourth purpose is to provide an application of the covalent kinase inhibitor and its pharmaceutical composition.
[0008] Technical solution: The covalent kinase inhibitor of the present invention has a structure of Formula I, II, III, IV or V, and also includes a pharmaceutically acceptable salt thereof,
[0009]
[0010]
[0011] in:
[0012] R1 and R2 are selected from C1-C4 alkyl or R1, R2 and the nitrogen to which they are attached together form a 4-7 membered heterocyclic ring containing 1-2 nitrogen, oxygen, or sulfur atoms, and the ring carbon atom is substituted by at least one hydrogen, hydroxyl, halogen, C1-C4 alkyl, halogen-substituted C1-C4 alkyl, or hydroxyl-substituted C1-C4 alkyl;
[0013] The kinase inhibitor nucleus is selected from:
[0014]
[0015] The present invention designs a method based on NO / NO2 — A kinase inhibitor of a release-type covalent warhead, wherein the covalent kinase inhibitor having a structure of Formula I has O 2-(α-methylene-α,β-unsaturated ketone)-azodiol salt warhead structure can covalently bind to the specific thiol group of protein kinase, and the O of azodiol salt is removed by covalent binding-mediated addition-elimination reaction. 2 Protection, triggering NO in situ release in a very small range. The covalent kinase inhibitor with the structure of formula II has an α-nitromethyl-α, β-unsaturated ketone warhead structure and uses the same mechanism to mediate NO2 by covalent binding reaction. — Released in a very small range. Covalent kinase inhibitors with structures of formula III, IV, and V have a ring-strained nitro-substituted warhead structure, which, mediated by ring strain, releases NO2 in a very small range after a nucleophilic substitution reaction with a specific thiol group of protein kinase. — .
[0016] The present invention is NO / NO2 — The releasable warhead groups were newly designed, so that the kinase inhibitors covalently bound to these warhead groups can remove the azodiol salt fragment through addition-elimination reaction after nucleophilic attack in the presence of thiol-containing target proteins in vitro / in vivo. 2 Protection, release of NO, and release of NO2 by the same mechanism or ring strain mechanism — On the one hand, covalent binding can inhibit the target enzyme containing sulfhydryl groups, and on the other hand, the released NO / NO2 — It can further produce nitrosylation modification on target kinases and interacting kinases, inhibit their autophosphorylation, prevent kinase signal transduction, and exert a synergistic effect.
[0017] The compounds designed in this invention have good covalent binding triggering specificity, NO / NO2 — High release efficiency, good biological activity, and covalent binding and NO / NO2 — The synergistic effect can effectively overcome the existing NO / NO2 — The insufficiency of donor drugs and covalent inhibitors. At the same time, due to the synergistic effect, the dosage of drugs can be reduced, thereby improving the patient's medication compliance, and significantly improving safety and reducing toxic side effects.
[0018] In the design of covalent kinase inhibitors of formula I, diazeniumdiolates have obvious advantages in selective and targeted release of NO. On the one hand, diazeniumdiolates are very unstable under physiological conditions and can automatically release 1 to 2 molecules of NO with a half-life ranging from a few seconds to a few hours. On the other hand, the O 2 The O connected to the nitrogen onium ion is called O 1 , the O connected to the olefinic nitrogen atom is O 2 ) after protection, it can be converted into a stable prodrug; O can be removed under specific conditions2 The protecting group is converted into an unstable azodiol anion, thereby achieving selective and targeted release of NO. At the same time, the covalent kinase inhibitor of formula II can also selectively and targetedly release NO2 through the same addition-elimination reaction mechanism. — In addition, the covalent kinase inhibitors of formula III, IV, and V are selective and targeted by ring tension. — release.
[0019] The present invention is based on covalent inhibition therapy and NO / NO2 — The application of donor drugs in the field of anti-tumor therapy uses the chemical group release advantages of covalent inhibitor warhead groups to obtain NO / NO2-based — A new class of azodiol salt drugs was designed to inhibit kinases with covalent warheads. 2 Protection method: The prodrug deprotection is carried out according to the mechanism of formula 1 or formula 2, and each HS-R3 is selected from one of the small molecule thiol compound glutathione, cysteine and protein BTK, HER1, HER2, Fgfr4, HER3, HER4, KRAS G12C.
[0020] Formula 1:
[0021]
[0022] Formula 2:
[0023]
[0024] Preferably, in the structure, R1 and R2 are selected from methyl, ethyl or R1, R2 and the N to which they are connected together form a 5-6 membered heterocycle, wherein the heterocycle is a morpholine ring, a piperidine ring, or a tetrahydropyrrole ring, and the ring carbon atom is substituted by at least one hydrogen, hydroxyl, fluorine, chlorine, bromine, methyl, ethyl, trifluoromethyl, hydroxymethyl, or hydroxyethyl; NR1R2 is further preferably selected from dimethylamino, methylethylamino, diethylamino, morpholinyl, tetrahydropyrrolyl, 2-hydroxymethyltetrahydropyrrolyl, piperidinyl, and 4-hydroxypiperidinyl.
[0025] Specifically, the covalent kinase inhibitor is most preferably selected from any of the following compounds:
[0026]
[0027]
[0028]
[0029] Furthermore, the above covalent kinase inhibitor forms a pharmaceutically acceptable salt with any of the following acids: hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, carbonic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, camphorsulfonic acid, citric acid, tartaric acid, malic acid, lactic acid, pyruvic acid, acetic acid, maleic acid, succinic acid, fumaric acid, salicylic acid, phenylacetic acid, ferulic acid or mandelic acid.
[0030] The method for preparing the covalent kinase inhibitor of the present invention comprises the following steps:
[0031] (1) When the covalent kinase inhibitor has the structural formula of Formula I or II,
[0032] (i) Compound 1 is reacted in the presence of paraformaldehyde, triethylenediamine and phenol to obtain intermediate 2;
[0033] (ii) intermediate 2 is reacted in the presence of p-toluenesulfonyl chloride and triethylamine to obtain intermediate 3;
[0034] (iii) intermediate 3 reacts with the corresponding azodiol salt or AgNO2 under the catalysis of 15-crown-5-ether to obtain the final product 4 or 5;
[0035]
[0036] (2) When the covalent kinase inhibitor has the structural formula III,
[0037] (i) the kinase inhibitor core 6 is reacted with 2,3-dibromopropionic acid under the catalysis of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to obtain compound 7;
[0038] (ii) Compound 7 reacts with nitromethane to obtain the final product 8;
[0039]
[0040] (3) When the covalent kinase inhibitor has the structural formula IV,
[0041] (i) tert-butyl 3-oxocyclobutylcarboxylate is reacted in the presence of hydroxylamine hydrochloride and sodium acetate to obtain oxime intermediate 10;
[0042] (ii) intermediate 10 reacts with urea peroxide and trifluoroacetic anhydride to obtain intermediate 11;
[0043] (iii) intermediate 11 reacts with kinase inhibitor core 6 to obtain final product 12;
[0044]
[0045] (4) When the covalent kinase inhibitor has a structural formula of Formula V, the kinase inhibitor core 6 is reacted with 2-bromo-1-(3,3-dinitroazetidine-1-yl)ethanone to obtain the final product 13;
[0046]
[0047] Among them, R1, R2, and the kinase inhibitor mother nucleus are defined as above;
[0048] The corresponding acid is reacted with the kinase inhibitor prepared by the above method to form a salt, thereby obtaining the pharmaceutically acceptable salt.
[0049] The covalent kinase inhibitor of the present invention and a pharmaceutically acceptable carrier form the pharmaceutical composition of the present invention, and can be specifically added with common pharmaceutical excipients such as flavorings, sweeteners, liquid / solid fillers, diluents, etc. to prepare common pharmaceutical preparations, such as tablets, capsules, syrups, suspensions, injections, etc.
[0050] The covalent kinase inhibitor and the pharmaceutical composition thereof described in the present invention are used to prepare drugs for treating and / or preventing proliferative diseases, delaying the progression of proliferative diseases, alleviating the symptoms of proliferative diseases, and assisting in the treatment of proliferative diseases and managing proliferative diseases.
[0051] Preferably, the proliferative disease is selected from tumors, rheumatic diseases, chronic inflammation, infectious mononucleosis.
[0052] Further preferably, the proliferative disease is selected from:
[0053] Gastric cancer, colorectal cancer, lung cancer (such as lung adenocarcinoma), breast cancer, liver cancer, prostate cancer, thyroid cancer, pancreatic cancer, bladder cancer, kidney cancer, brain tumor, neck cancer, CNS (central nervous system) cancer, malignant glioma, myeloproliferative disease, atherosclerosis, leukemia, pulmonary fibrosis, lymphoma, rheumatic disease, chronic inflammation, non-lymphoreticular tumors, cryoglobulinemia, papular mucinosis, familial splenic anemia, multiple myeloma, amyloidosis, solitary plasmacytoma, heavy chain disease, light chain disease, malignant lymphoma, chronic lymphocytic leukemia, monocytic leukemia, semi-molecular disease, primary macroglobulinemia, primary macroglobulinemia purpura, secondary benign monoclonal gamma Gammopathies, osteolytic lesions, acute lymphocytic leukemia, lymphoblastoma, some non-Hodgkin lymphomas, Sezary syndrome, infectious mononucleosis, acute histiocytosis, hairy cell leukemia, Hodgkin lymphoma, colon cancer, rectal cancer, intestinal polyps, diverticulitis, colitis, pancreatitis, hepatitis, small cell lung cancer, neuroblastoma, neuroendocrine cell tumors, islet cell tumors, medullary thyroid cancer, melanoma, uterine cancer, chronic hepatitis, cirrhosis, ovarian cancer, retinoblastoma, cholecystitis, squamous cell carcinoma of the head and neck, digestive tract malignancies, non-small cell lung cancer, cervical cancer, testicular tumors, bladder cancer, myeloma, or bone malignancies (such as osteosarcoma).
[0054] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages:
[0055] 1. This type of covalent kinase inhibitor can effectively covalently bind to the target enzyme and effectively release NO / NO2 — On the one hand, covalent binding can inhibit the target enzyme containing sulfhydryl groups, and on the other hand, the NO / NO2 released — It can further produce nitrosylation modification on target kinases and interacting kinases, inhibit their autophosphorylation, prevent kinase signal transduction, and exert synergistic effects; it is also selective and reduces non-target inhibition;
[0056] 2. This type of covalent kinase inhibitor has significant inhibitory activity at the molecular level, cellular level and animal level, acting on a variety of enzymes related to malignant proliferation and malignant proliferating cells, and inhibiting tumor growth in animals without producing obvious adverse reactions;
[0057] 3. The preparation method of the compound is simple and universal, which is conducive to the expansion of various structures. BRIEF DESCRIPTION OF THE DRAWINGS
[0058] Figure 1 It is the mass spectrometry verification result of the covalent binding of compound I1 to Bruton's tyrosine kinase (BTK);
[0059] Figure 2It is the mass spectrometry verification result of the covalent binding of I3 compound to Bruton's tyrosine kinase (BTK);
[0060] Figure 3 The NO release results of compound I1 in BTK storage solution, rat liver microsomes, rat plasma, GSH solution, and the NO release results of compound I1 in B cell lymphoma Daudi cells;
[0061] Figure 4 These are the stability test results of compounds I1-I6 in rat plasma and GSH solution;
[0062] Figure 5 It is the Kinact / Ki parameter test result of compound I1;
[0063] Figure 6 is the kinase profile test result of compound I1;
[0064] Figure 7 This is the result of the nude mouse experiment with compound I1;
[0065] Figure 8 It is the verification result of the co-localization of NO release and Bruton's tyrosine kinase (BTK) of compound I1 in cells;
[0066] Fig. 9 The NO released by I1 compound causes increased nitrosylation and decreased phosphorylation / blocked phosphorylation signal transduction of Bruton's tyrosine kinase (BTK). DETAILED DESCRIPTION
[0067] The technical solution of the present invention is further described below in conjunction with embodiments.
[0068] Example 1: Preparation of Compound I1
[0069]
[0070] 1. Dissolve 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl]-1-piperidinyl]-2-propene-1-one (ibrutinib) (10 g, 0.023 mol) in 50 ml of 1,4-dioxane, add paraformaldehyde (40.9 g, 0.454 mol), triethylenediamine (3.82 g, 0.034 mol), phenol (1.6 g, 0.017 mol), and react at 60°C for 3 days. Concentrate under reduced pressure to remove the solvent, then extract with ethyl acetate (50 mL), wash the organic layer with water and saturated brine 3 times each, dry over anhydrous sodium sulfate, concentrate, and perform column chromatography (petroleum ether / ethyl acetate = 5 / 1, v / v) to obtain white solid V1. 1H NMR(500MHz,Chloroform-d)δ8.25(s,1H),7.60–7.54(m,3H),7.40–7.32(m,3H),7.18(s,1 H),7.12–6.99(m,4H),6.98–6.92(m,3H),6.82(s,1H),5.76(d,J=12.5Hz,1H),5.59(d,J=12 .5Hz,1H),5.00(s,1H),4.37(t,J=5.5Hz,1H),4.28–4.14(m,3H),3.94(s,1H),3.87(s,1H) ,3.52(d,J=8.4Hz,3H),2.10(s,1H),2.01(s,1H),1.96(s,1H),1.91(s,1H).HRMS(ESI):m / z calcd.for C 26 H 26 N6O3,[M+H] + :471.2066,found:471.2061.
[0071] 2. Dissolve V1 (200 mg, 0.43 mmol) in 15 ml of dichloromethane, add p-toluenesulfonyl chloride (90 mg, 0.47 mmol) and triethylamine (18.3 mg, 0.18 mmol), react at room temperature for 10 h under nitrogen protection, then extract with ethyl acetate, wash the organic layer with water and saturated brine three times each, dry over anhydrous sodium sulfate, and obtain white solid V2 by column chromatography (petroleum ether / ethyl acetate = 20 / 1, v / v). 1 H NMR(500MHz,Chloroform-d)δ8.00(s,1H),7.81–7.75(m,3H),7.69–7.63(m,3H),7.40–7.3 0(m,5H),7.10(tt,J=7.6,2.0Hz,1H),7.04–6.94(m,7H),6.72(s,1H),5.84(d,J=12.3Hz,1H ),5.61(d,J=12.5Hz,1H),4.94(s,1H),4.49(s,2H),4.01(s,1H),3.94(s,1H),3.51(s,2H) ,2.43(t,J=1.0Hz,4H),2.08(s,1H),2.01(s,1H),1.96(s,1H),1.88(s,1H).HRMS(ESI):m / z calcd.forC 33 H 32 N6O5S,[M+H] + :625.2155,found:624.2151.
[0072] 3. The p-toluenesulfonyl chloride substituted product V2 (300 mg, 0.48 mmol) was dissolved in 20 ml DMSO, and dimethylaminoazolinium diol salt (305 mg, 2.40 mmol) was added. The mixture was reacted at room temperature for 10 h under nitrogen protection, and then extracted with ethyl acetate. The organic layer was washed with water and saturated brine for 3 times each, dried over anhydrous sodium sulfate, and purified by column chromatography (petroleum ether / ethyl acetate = 10 / 1, v / v) to obtain a white solid I1. 1 H NMR(500MHz,Chloroform-d)δ8.63(s,1H),7.69–7.63(m,3H),7.39–7.32(m,3H),7.12 –7.05(m,1H),7.08–6.96(m,7H),6.72(s,1H),5.84(d,J=12.4Hz,1H),5.59(d,J=12.5H z,1H),5.00(s,1H),4.53(d,J=0.9Hz,2H),3.94(s,1H),3.87(s,1H),3.52(d,J=6.2Hz ,3H),2.96(s,6H),2.08(s,1H),2.01(s,1H),1.96(s,1H),1.88(s,1H).HRMS(ESI):m / z calcd.forC 28 H 31 N9O4,[M+H] + :558.2499,found:558.2498.
[0073] Example 2: Preparation of Compound I2
[0074]
[0075] Refer to the synthesis method of Example 1. 1H NMR(500MHz,Chloroform-d)δ8.25(s,1H),7.69–7.63(m,3H),7.39–7.32(m,3H),7.12(tt,J=7.5,2.0 Hz,1H),7.04–6.75(m,7H),6.52(s,1H),5.64(d,J=12.4Hz,1H),5.59(d,J=12.5Hz,1H),4.86(s,1H),4 .53(d,J=12.3Hz,1H),4.32(d,J=12.3Hz,1H),3.78(s,1H),3.77(s,1H),3.71(s,2H),3.53(d,J=10.4 Hz,3H),2.93(s,3H),2.08(s,1H),2.01(s,1H),1.96(s,1H),1.88(s,1H),1.19(s,3H).HRMS(ESI):m / z calcd.forC 29 H 33 N9O4,[M+H] + :572.2656,found:572.2652.
[0076] Example 3: Preparation of Compound I3
[0077]
[0078] Refer to the synthesis method of Example 1. 1 H NMR(500MHz,Chloroform-d)δ8.35(s,1H),7.89–7.83(m,3H),7.40–7.32(m,3H),7.12(tt,J=7.5,2.1Hz,1H ),7.13–6.99(m,7H),6.89(s,1H),5.84(d,J=12.4Hz,1H),5.65(d,J=12.5Hz,1H),5.15(s,1H),4.66(d,J=1 2.3Hz,1H),4.48(d,J=12.3Hz,1H),4.01(s,1H),3.94(s,1H),3.73(d,J=12.4Hz,2H),3.65(d,J=12.5Hz,2H ),3.53(d,J=10.4Hz,3H),2.08(s,1H),2.01(s,1H),1.96(s,1H),1.88(s,1H),1.17(s,6H).HRMS(ESI):m / z calcd.forC 30 H 35 N9O4,[M+H] +:586.2812,found:586.2807.
[0079] Example 4: Preparation of Compound I4
[0080]
[0081] Refer to the synthesis method of Example 1. 1 H NMR(500MHz,Chloroform-d)δ8.29(s,1H),7.69–7.63(m,3H),7.40–7.32(m,3H),7.09(tt,J=7.6,2. 0Hz,1H),7.04–6.94(m,7H),6.72(s,1H),5.84(d,J=12.4Hz,1H),5.59(d,J=12.5Hz,1H),5.00(s,1H ),4.53(d,J=0.9Hz,2H),4.01(s,1H),3.94(s,1H),3.68(d,J=7.1Hz,5H),3.53(d,J=10.4Hz,3H),3. 29(d,J=8.4Hz,5H),2.08(s,1H),2.01(s,1H),1.96(s,1H),1.88(s,1H).HRMS(ESI):m / zcalcd.forC 30 H 33 N9O5,[M+H] + :600.2605,found:600.2601.
[0082] Example 5: Preparation of Compound I5
[0083]
[0084] Refer to the synthesis method of Example 1. 1H NMR(500MHz,Chloroform-d)δ8.25(s,1H),7.51–7.63(m,3H),7.40–7.28(m,3H),7.18(tt,J=7.5,2.0H z,1H),7.04–6.88(m,7H),6.66(s,1H),5.65(d,J=12.5Hz,1H),5.59(d,J=12.5Hz,1H),5.00(s,1H),4.5 3(d,J=12.3Hz,1H),4.48(d,J=12.3Hz,1H),4.01(s,1H),3.94(s,1H),3.53(d,J=10.4Hz,3H),3.27(d,J =2.4Hz,5H),2.08(s,1H),2.01(s,1H),1.96(s,1H),1.88(s,1H),1.83(d,J=3.7Hz,5H).HRMS(ESI):m / z calcd.for C 30 H 33 N9O4,[M+H] + :584.2656,found:584.2651.
[0085] Example 6: Preparation of Compound I6
[0086]
[0087] Refer to the synthesis method of Example 1. 1 H NMR(500MHz,Chloroform-d)δ8.69(s,1H),7.69–7.63(m,3H),7.64–7.32(m,3H),7.23(tt,J=7.6,2.0Hz,1H ),7.14–6.92(m,7H),6.72(s,1H),5.84(d,J=12.4Hz,1H),5.59(d,J=12.5Hz,1H),5.25(s,1H),4.53(d,J=1 2.3Hz,1H),4.48(d,J=12.3Hz,1H),4.01(s,1H),3.94(s,1H),3.53(d,J=10.4Hz,3H),3.38(s,2H),3.31(s, 2H),2.08(s,1H),2.01(s,1H),1.96(s,1H),1.88(s,1H),1.78(d,J=2.6Hz,5H),1.60(s,2H).HRMS(ESI):m / z calcd.for C 31 H 35 N9O4,[M+H] +:598.2812,found:598.2808.
[0088] Example 7: Preparation of Compound I7
[0089]
[0090] Referring to the synthesis method of Example 1, the p-toluenesulfonyl chloride substituted product V2 (300 mg, 0.48 mmol) was dissolved in 10 ml of anhydrous ether, and AgNO2 (369 mg, 2.40 mmol) was added. The reaction was carried out at room temperature in the dark under nitrogen protection for 10 h, and then the solvent was concentrated under reduced pressure. The product was extracted with ethyl acetate, and the organic layer was washed with water and saturated brine three times each, dried over anhydrous sodium sulfate, and purified by column chromatography (petroleum ether / ethyl acetate = 10 / 1, v / v) to obtain a white solid I7. 1 H NMR(500MHz,Chloroform-d)δ8.66(s,1H),7.77–7.64(m,3H),7.47–7.39(m,3H) ,7.11–6.94(m,9H),6.72(s,1H),5.75(d,J=12.5Hz,1H),5.58(d,J=12.3Hz,1H) ,5.15(s,1H),4.44(d,J=3.1Hz,3H),3.87(d,J=1.8Hz,3H),3.52(d,J=2.0Hz,3H ),2.08(s,1H),2.01(s,1H),1.96(s,1H),1.84(s,1H).HRMS(ESI):m / zcalcd.for C 26 H 25 N7O4,[M+H]+:500.1968,found:500.1965.
[0091] Example 8: Preparation of Compound I8
[0092]
[0093] 1. Dissolve 3-(4-phenoxyphenyl)-1-(piperidin-3-yl)-1H-pyrazolo[3,4-D]pyrimidin-4-amine (ibrutinib intermediate) (10 g, 0.02587 mol) in 50 ml of dichloromethane, add EDCI (9.91 g, 0.05174 mol), triethylamine (5.24 g, 0.05174 mol), 2,3-dibromopropionic acid (5.99 g, 0.02587 mol), react at room temperature for 36 hours, concentrate under reduced pressure to remove the solvent, and then extract with ethyl acetate (100 mL), wash the organic layer with water and saturated brine three times each, dry over anhydrous sodium sulfate, concentrate, and perform column chromatography (petroleum ether / ethyl acetate = 1 / 1, v / v) to obtain white solid V3.1 HNMR(500MHz,Chloroform-d)δ8.75(s,1H),7.68–7.61(m,3H),7.39–7.32(m, 3H),7.11–7.04(m,1H),7.08(s,2H),7.04–6.94(m,5H),6.72(s,1H),5.00(s,1 H),4.21(s,1H),4.01(s,1H),3.94(s,1H),3.81(d,J=1.4Hz,3H),3.47(d,J=11 .9Hz,2H),2.08(s,1H),2.01(s,1H),1.96(s,1H),1.92(s,1H).HRMS(ESI):m / z calcd.for C 25 H 24 Br2N6O2,[M+H] + :599.0327,found:599.0325.
[0094] 2. Dissolve V3 (10 g, 0.01666 mol) in 50 ml of ethanol, add nitromethane (1.5 g, 0.02499 mol), reflux for 24 hours, concentrate under reduced pressure to remove the solvent, then extract with ethyl acetate (100 mL), wash the organic layer with water and saturated brine three times each, dry over anhydrous sodium sulfate, concentrate, and perform column chromatography (petroleum ether / ethyl acetate = 10 / 1, v / v) to obtain white solid I8. 1 H NMR(500MHz,Chloroform-d)δ8.35(s,1H),7.60–7.54(m,2H),7.39–7.32(m,2H),7.11–7 .06(m,1H),7.08(s,1H),7.09–6.94(m,5H),6.81(s,1H),5.00(s,1H),4.49(s,1H),4.12( s,1H),3.62(s,1H),3.47(d,J=1.1Hz,2H),3.40(s,1H),3.18(d,J=4.9Hz,1H),2.68(d,J =5.1Hz,1H),2.08(s,1H),1.97(d,J=10.6Hz,2H),1.84(s,1H).HRMS(ESI):m / zcalcd.for C 26 H 25 N7O4,[M+H] + :500.1968,found:500.1964.
[0095] Example 9: Preparation of Compound I9
[0096]
[0097] 1. Dissolve tert-butyl 3-oxocyclobutylcarboxylate (1 g, 0.005875 mol), sodium acetate (1.60 g, 0.01175 mol) and hydroxylamine hydrochloride (0.8165 g, 0.01175 mol) in 50 ml of ethanol, reflux for 24 hours, concentrate under reduced pressure to remove the solvent, and then extract with ethyl acetate (100 mL). Wash the organic layer with water and saturated brine three times each, dry over anhydrous sodium sulfate, concentrate, and perform column chromatography (petroleum ether / ethyl acetate = 50 / 1, v / v) to obtain colorless oil V4. 1 H NMR(500MHz,Chloroform-d)δ2.82(s,1H),2.69(d,J=13.0Hz,2H),2.62(d,J=13.0Hz,2H),1.42(s,9H).HRMS(ESI):m / zcalcd.for C9H 14 O3,[M+H] + :171.0943,found:171.0941.
[0098] 2. Dissolve V4 (500 mg, 2.94 mmol), trifluoroacetic anhydride (926.06 mg, 4.41 mmol), urea peroxide (414.85 mg, 4.41 mmol) and sodium dihydrogen phosphate (529.09 mg, 4.41 mmol) in anhydrous acetonitrile, reflux for 4 hours, filter, and concentrate under reduced pressure to remove the solvent in the filtrate, then extract with ethyl acetate (100 mL), wash the organic layer with water and saturated brine three times each, dry over anhydrous sodium sulfate, concentrate, and obtain white solid V5 by column chromatography (petroleum ether / ethyl acetate = 10 / 1, v / v). 1 H NMR(500MHz,Chloroform-d)δ4.15(s,1H),2.78(d,J=13.0Hz,2H),2.69(d,J=13.0Hz,2H),2.50(s,1H).HRMS(ESI):m / z calcd.for C5H7NO4,[M+H] + :146.0375,found:146.0370.
[0099] 3. Dissolve 3-(4-phenoxyphenyl)-1-(piperidin-3-yl)-1H-pyrazolo[3,4-D]pyrimidin-4-amine (ibrutinib intermediate) (10 g, 0.02587 mol) in 50 ml of dichloromethane, add EDCI (9.91 g, 0.05174 mol), triethylamine (5.24 g, 0.05174 mol), V5 (4.51 g, 0.031044), react at room temperature for 24 hours, concentrate under reduced pressure to remove the solvent, and then extract with ethyl acetate (100 mL), wash the organic layer with water and saturated brine three times each, dry over anhydrous sodium sulfate, concentrate, and obtain white solid I9 by column chromatography (petroleum ether / ethyl acetate = 50 / 1, v / v). 1 H NMR(500MHz,Chloroform-d)δ8.25(s,1H),7.60–7.54(m,3H),7.39–7.32(m,3H),7.1 2–7.05(m,1H),7.08(s,1H),7.05–6.95(m,5H),6.81(s,1H),5.00(s,1H),4.22(s,1H ),4.09(s,1H),3.59(s,1H),3.51(s,2H),2.69(d,J=13.0Hz,2H),2.64(s,1H),2.53( d,J=13.0Hz,2H),2.08(s,1H),2.01(s,1H),1.96(s,1H),1.92(s,1H).HRMS(ESI):m / z calcd.for C 27 H 27 N7O4,[M+H] + :514.2125,found:514.2119.
[0100] Example 10: Compound I 10 Preparation
[0101]
[0102] 3-(4-phenoxyphenyl)-1-(piperidin-3-yl)-1H-pyrazolo[3,4-D]pyrimidin-4-amine (ibrutinib intermediate) (10g, 0.02587mol) was dissolved in 50ml of dichloromethane and precooled on an ice bath for 10 minutes. 2-Bromo-1-(3,3-dinitroazetidine-1-yl)ethanone (6.2g, 0.02328mol) was dissolved in 10ml of dichloromethane and then dripped into the previous ibrutinib intermediate solution. After reacting in an ice bath for 30 minutes, it was moved to room temperature for 2 hours. The solvent was removed by concentration under reduced pressure, and then extracted with ethyl acetate (100mL). The organic layer was washed with water and saturated brine 3 times each, dried over anhydrous sodium sulfate, concentrated, and column chromatography (petroleum ether / ethyl acetate = 30 / 1, v / v) was obtained to obtain a white solid I 10 . 1 H NMR(500MHz,Chloroform-d)δ8.71(s,1H),7.69–7.63(m,3H),7.40–7.32(m,3H),7.08 (tt,J=7.5,2.1Hz,1H),7.04–6.95(m,7H),6.72(s,1H),4.83(s,1H),3.56(s,1H),3.51 (s,2H),3.43(s,2H),3.18(d,J=12.4Hz,1H),3.13(d,J=12.3Hz,1H),3.06(s,1H),2.82 (s,1H),2.70(s,1H),2.00(s,1H),1.96(s,1H),1.82(d,J=12.5Hz,2H).HRMS(ESI):m / z calcd.for C 27 H 27 N9O6,[M+H] + :574.2084,found:574.2080.
[0103] Example 11: Preparation of Compound II
[0104]
[0105] Refer to the synthesis method of Example 1. 1H NMR (500MHz, Methanol-d4) δ7.90 (s, 1H), 7.63 (t, J = 8.4Hz, 1H), 7.51 (d, J = 9.1Hz, 1H), 7.29 (s, 1H), 5.57 (d, J = 105.3Hz, 1H), 4.9 7(s,2H),4.08(s,J=2.2Hz,3H),3.93(t,J=10.6Hz,2H),3.06(s,6H),2.13–2.07(m,3H),1.95(s,2H),1.45(s,2H).HRMS(ESI):m / z calcd.forC 26 H 28 Cl2FN7O5,[M+H] + :608.1513,found:608.1509.
[0106] Example 12: Preparation of Compound II2
[0107]
[0108] Refer to the synthesis method of Example 1. 1 H NMR(500MHz,Chloroform-d)δ8.68(s,1H),8.28(s,1H),7.45(s,1H),7.35(s,2 H),5.57(s,1H),5.37(s,1H),5.00–4.89(m,2H),4.79(s,1H),4.04(s,3H),3.9 3–3.87(m,2H),3.82–3.66(m,2H),3.36(q,J=7.1Hz,2H),2.96(s,3H),2.08–2. 03(m,2H),1.97–1.92(m,2H),1.13(t,J=7.1Hz,3H).HRMS(ESI):m / zcalcd.forC 27 H 30 Cl2FN7O5,[M+H] + :622.1670,found:622.1670.
[0109] Example 13: Preparation of Compound II3
[0110]
[0111] Refer to the synthesis method of Example 1. 1H NMR(300MHz,Chloroform-d)δ8.62(s,1H),8.09(s,1H),8.00(s,1H),7.57–7.52(m,1H),7.39(d,J=9.5Hz,1H),5.56(s,1H),5.35(s,1H),4.96( s,2H),4.81(s,1H),4.01(s,3H),3.89(s,2H),3.67(s,2H),3.13(q,J=6.9Hz,4H),1.99(d,J=29.2Hz,4H),1.08(t,J=7.0Hz,6H).HRMS(ESI):m / z calcd.for C 28 H 32 Cl2FN7O5,[M+H] + :636.1826,found:636.1817.
[0112] Example 14: Preparation of Compound II4
[0113]
[0114] Refer to the synthesis method of Example 1. 1 H NMR(500MHz,Chloroform-d)δ8.68(s,1H),8.28(s,1H),7.44(s,1H),7.35(s,2H),5.57(s,1H),5.37(s,1H),4.96(s,2H),4.78(s,1H), 4.04(s,3H),3.91(t,J=9.7Hz,2H),3.85(t,J=4.8Hz,4H),3.76–3.65(m,2H),3.45(t,J=4.7Hz,4H),2.11–1.97(m,4H).HRMS(ESI):m / z calcd.for C 28 H 30 Cl2FN7O6,[M+H] + :650.1619,found:650.1619.
[0115] Example 15: Preparation of Compound II5
[0116]
[0117] Refer to the synthesis method of Example 1. 1H NMR(500MHz,Chloroform-d)δ8.41(s,1H),7.82(s,1H),7.63(t,J=8.2Hz,1H),7.46( dd,J=8.8,1.8Hz,1H),5.66(s,1H),5.45(s,1H),4.96(s,2H),4.87(dd,J=6.7,3.3Hz ,1H),4.04(s,3H),3.41–3.37(m,4H),3.37–3.30(m,4H),2.08(ddd,J=12.2,8.2,3.7 Hz,2H),1.73(p,J=5.8Hz,4H),1.58–1.50(m,2H),1.35–1.28(m,2H).HRMS(ESI):m / z calcd.for C 29 H 32 Cl2FN7O5,[M+H] + :648.1826,found:648.1826.
[0118] Example 16: Preparation of Compound II6
[0119]
[0120] Refer to the synthesis method of Example 1. 1 H NMR(500MHz,Chloroform-d)δ8.61(s,1H),7.95(t,J=8.5Hz,1H),7.69(s,1H),7.29(s,1H),7.24(dd,J=8.9,1.9Hz,1H),5.50(s,1H),5 .29(s,1H),4.82(s,1H),4.00(s,3H),3.73(q,J=7.0Hz,4H),3.68(s,9H),1.95(s,2H),1.93–1.87(m,2H),1.25(d,4H).HRMS(ESI):m / z calcd.for C 29 H 32 Cl2FN7O6,[M+H] + :664.1775,found:664.1764.
[0121] Example 17: Preparation of Compound II7
[0122]
[0123] Refer to the synthesis method of Example 7. 1H NMR(500MHz,Chloroform-d)δ8.76(s,1H),8.50(s,1H),7.62(d,J=7.5Hz,1H),7.50(d,J=7.5Hz,1H),7.41(s,1H),7.09(s,1H),5.76(d,J=12 .4Hz,1H),5.53(d,J=12.5Hz,1H),4.86(s,1H),4.45(s,2H),3.80(s,3H),3.49(s,2H),3.41(s,2H),2.18(s,2H),2.00(s,2H).HRMS(ESI):m / z calcd.for C 24 H 22 Cl2FN5O5,[M+H] + :550.0982,found:550.0978.
[0124] Example 18: Preparation of Compound II8
[0125]
[0126] Refer to the synthesis method of Example 8. 1 H NMR(500MHz,Chloroform-d)δ9.26(s,1H),8.50(s,1H),7.62(d,J=7.5Hz,1H),7.50(d,J=7.5Hz,1H),7.41(s,1H),7.09(s,1H),4.83(s,1H),4.5 3(s,1H),3.80(s,3H),3.49(s,2H),3.33(d,J=3.7Hz,4H),3.18(d,J=4.9 Hz,1H),2.68(d,J=5.1Hz,1H),2.13(s,2H),2.00(s,2H).HRMS(ESI):m / z calcd.for C 24 H 22 Cl2FN5O5,[M+H] + :550.0982,found:550.0979.
[0127] Example 19: Preparation of Compound II9
[0128]
[0129] Refer to the synthesis method of Example 9. 1H NMR(500MHz,Chloroform-d)δ9.35(s,1H),8.54(s,1H),7.62(d,J=7.5Hz,1H),7.50(d,J=7.5Hz,1H),7.37(s,1H),7.09(s,1H),4.83(s,1H ),4.22(s,1H),3.79(s,3H),3.51(s,2H),3.38(s,2H),2.69(d,J=13.0Hz,2H),2.57–2.50(m,3H),2.18(s,2H),2.03(s,2H).HRMS(ESI):m / z calcd.for C 25 H 24 Cl2FN5O5,[M+H] + :564.1139,found:564.1134.
[0130] Example 20: Compound II 10 Preparation
[0131]
[0132] Refer to the synthesis method of Example 10. 1 H NMR(500MHz,Chloroform-d)δ9.35(s,1H),8.54(s,1H),7.60(d,J=7.5Hz,1H),7.50(d,J=7.5Hz,1H),7.37(s,1H),7.09(s,1H),4. 83(s,1H),3.81(s,3H),3.51(s,2H),3.44(s,2H),3.17(s,2H),3.03(s,2H),2.75(s,2H),2.07(s,2H),2.03(s,2H).HRMS(ESI):m / z calcd.for C 25 H 24 Cl2FN7O7,[M+H] + :624.1098,found:624.1095.
[0133] Example 21: Preparation of Compound III1
[0134]
[0135] Refer to the synthesis method of Example 1. 1H NMR (500MHz, Chloroform-d) δ9.04 (s, 1H), 7.58 (d, J = 10.6Hz, 3H), 6.65 (s, 1H), 5. 84(s,1H),5.54(s,1H),4.86(d,J=2.5Hz,2H),4.51(d,J=7.8Hz,1H),4.28(s,1H),4 .08–3.99(m,2H),3.98(d,J=1.6Hz,6H),3.78–3.73(m,1H),3.61(td,J=12.0,2.6H z,1H),2.92(s,6H),2.10(d,J=12.9Hz,1H),1.95(d,J=12.1Hz,1H).HRMS(ESI):m / z calcd.for C 27 H 31 Cl2N7O6,[M+Na] + :642.1605,found:642.1598.
[0136] Example 22: Preparation of Compound III2
[0137]
[0138] Refer to the synthesis method of Example 1. 1 H NMR(500MHz,Chloroform-d)δ9.04(s,1H),7.59(d,J=7.8Hz,2H),7.55(d,J=8.8Hz,1H),6.65(s, 1H),5.79(s,1H),5.51(s,1H),4.98–4.88(m,2H),4.52–4.45(m,1H),4.26(s,1H),4.03(td,J=13. 4,12.7,7.4Hz,2H),3.98(d,J=1.8Hz,6H),3.75(d,J=11.9Hz,1H),3.65–3.57(m,1H),3.04(q,J= 7.1Hz,4H),2.12(d,J=13.7Hz,1H),1.93(d,J=12.6Hz,1H),1.01(t,J=7.1Hz,6H).HRMS(ESI):m / z calcd.forC 29 H 35 Cl2N7O6,[M+Na] + :670.1918,found:670.1915.
[0139] Example 23: Preparation of Compound III3
[0140]
[0141] Refer to the synthesis method of Example 1. 1 H NMR(500MHz,Chloroform-d)δ9.05(s,1H),7.58(d,J=10.1Hz,3H),6.65(s,1H),5.82(s,1H) ,5.53(s,1H),4.87(s,2H),4.50(d,J=7.9Hz,1H),4.28(s,1H),4.04(dd,J=13.6,4.9Hz,2H), 3.97(d,J=1.5Hz,6H),3.77–3.73(m,1H),3.61(td,J=11.9,2.5Hz,1H),3.27(t,J=5.6Hz,4H) ,2.12–2.06(m,1H),1.98–1.92(m,1H),1.70–1.66(m,4H),1.47–1.43(m,2H).HRMS(ESI):m / z calcd.for C 30 H 35 Cl2N7O6,[M+Na] + :682.1918,found:670.1913.
[0142] Example 24: Preparation of Compound III4
[0143]
[0144] Refer to the synthesis method of Example 1. 1 H NMR(300MHz,Chloroform-d)δ9.05(s,1H),7.65–7.52(m,3H),6.64(s,1H),5.81(s, 1H),5.53(s,1H),4.89(s,2H),4.55–4.42(m,1H),4.25(d,J=13.2Hz,1H),4.04(dd,J =10.3,3.9Hz,2H),3.98(s,6H),3.77(dd,J=5.9,3.6Hz,4H),3.61(td,J=11.9,2.5H z,1H),3.43–3.25(m,4H),2.12(d,J=12.6Hz,1H),2.06–1.82(m,2H).HRMS(ESI):m / z calcd.for C 29 H 33 Cl2N7O7,[M+Na] + :684.1711,found:684.1702.
[0145] Example 25: Preparation of Compound III5
[0146]
[0147] Refer to the synthesis method of Example 1. 1 H NMR(300MHz,Chloroform-d)δ9.04(s,1H),7.60(s,3H),6.65(s,1H),5.96( s,1H),5.56(s,1H),4.85–4.67(m,2H),4.58(s,1H),4.34(s,1H),4.03(s,2H ),3.99(d,J=3.2Hz,6H),3.86(d,J=11.0Hz,1H),3.78(d,J=7.8Hz,1H),3.6 6(s,1H),3.63–3.51(m,2H),3.42(s,2H),2.10–1.75(m,7H).HRMS(ESI):m / z calcd.forC 30 H 35 Cl2N7O7,[M+Na] + :698.1867,found:698.1861.
[0148] Example 26: Preparation of Compound III6
[0149]
[0150] Refer to the synthesis method of Example 1. 1 H NMR(500MHz,Chloroform-d)δ9.06(s,1H),7.59(d,J=8.2Hz,3H),6.65(s,1H),5.84 (s,1H),5.54(s,1H),4.87(s,2H),4.54–4.49(m,1H),4.32–4.26(m,1H),4.07–4.00 (m,2H),3.98(s,6H),3.87–3.82(m,1H),3.75(d,J=11.8Hz,1H),3.64–3.59(m,3H), 3.23–3.18(m,2H),1.97–1.91(m,3H),1.74–1.66(m,4H).HRMS(ESI):m / zcalcd.for C 30 H 35 Cl2N7O7,[M+Na] + :698.1867,found:698.1856.
[0151] Example 27: Preparation of Compound III7
[0152]
[0153] Refer to the synthesis method of Example 7. 1 H NMR(500MHz,Chloroform-d)δ8.55(s,1H),7.94(s,1H),7.74(s,1H),7.65(s,1H),7.54 (s,1H),7.44(s,1H),6.79(s,1H),5.76(d,J=12.4Hz,1H),5.53(d,J=12.5Hz,1H),4.44 (d,J=12.3Hz,1H),4.35(d,J=12.5Hz,1H),4.16(s,1H),4.05(s,1H),3.99(s,1H),3.86 (s,6H),3.80(d,J=13.2Hz,2H),3.75(s,1H),2.07(s,1H),1.94(s,1H).HRMS(ESI):m / z calcd.for C 25 H 25 Cl2N5O6,[M+H] + :562.1182,found:562.1180.
[0154] Example 28: Preparation of Compound III8
[0155]
[0156] Refer to the synthesis method of Example 8. 1 H NMR(500MHz,Chloroform-d)δ8.55(s,1H),7.94(s,1H),7.74(s,1H),7.65(s,1H ),7.54(s,1H),7.09(s,1H),6.79(s,1H),4.58(s,1H),4.21(s,1H),3.98(s,1H), 3.92(s,1H),3.87(s,6H),3.81(d,J=3.1Hz,2H),3.75(s,1H),3.60(s,1H),2.82( d,J=4.9Hz,1H),2.75(d,J=4.9Hz,1H),2.07(s,1H),1.96(s,1H).HRMS(ESI):m / z calcd.for C 25 H 25 Cl2N5O6,[M+H] + :562.1182,found:562.1179.
[0157] Example 29: Preparation of Compound III9
[0158]
[0159] Refer to the synthesis method of Example 9. 1 H NMR(500MHz,Chloroform-d)δ8.60(s,1H),7.94(s,1H),7.74(s,1H),7.63(s,1H) ,7.57(s,1H),7.12(s,1H),6.79(s,1H),4.22(s,1H),4.17(s,1H),3.99(s,1H),3 .89(s,6H),3.81(d,J=4.0Hz,2H),3.76(s,1H),3.72(s,1H),2.90(d,J=13.0Hz,2 H),2.58(s,1H),2.40(d,J=13.0Hz,2H),2.07(s,1H),1.94(s,1H).HRMS(ESI):m / z calcd.for C 26 H 27 Cl2N5O6,[M+H] + :576.1338,found:576.1334.
[0160] Example 30: Compound III 10 Preparation
[0161]
[0162] Refer to the synthesis method of Example 10. 1 H NMR(500MHz,Chloroform-d)δ8.60(s,1H),7.94(s,1H),7.65(s,1H),7.57(s,1H),7.27(s,1H),6.79(s,1H),4.06(s,1H),3.99(s,1H),3.91( s,6H),3.82(d,J=12.3Hz,1H),3.78–3.70(m,5H),3.62(s,1H),3.51(s,2H),3.44(s,2H),3.02(s,1H),1.86(d,J=8.1Hz,2H).HRMS(ESI):m / z calcd.for C 26 H 27 Cl2N7O8,[M+H] + :636.1298,found:636.1295.
[0163] Example 31: Preparation of Compound IV
[0164]
[0165] Refer to the synthesis method of Example 10. 1 H NMR(500MHz,Chloroform-d)δ9.79(s,1H),8.27(d,J=4.9Hz,1H),7.84(d,J=0.9 Hz,2H),7.43–7.36(m,2H),7.24(d,J=6.6Hz,3H),7.09(d,J=17.7Hz,2H),6.99( s,1H),4.61(s,2H),3.82(d,J=12.4Hz,6H),3.69(d,J=12.5Hz,1H),3.57(d,J=1 2.5Hz,1H),3.43(s,4H),2.89(s,3H),2.74(s,2H),2.32(s,6H).HRMS(ESI):m / z calcd.for C 30 H 36 N 10 O6,[M+H] + :633.2814,found:633.2810.
[0166] Example 32: Preparation of Compound V
[0167]
[0168] Refer to the synthesis method of Example 10. 1 H NMR(500MHz,Chloroform-d)δ8.38(d,J=4.9Hz,1H),7.75(s,1H),7.31(t,J=7.5Hz,1H ),7.14(dd,J=7.5,2.0Hz,1H),7.06(d,J=4.9Hz,1H),6.88(dd,J=7.5,2.0Hz,1H),3.7 5(s,1H),3.61(s,2H),3.56(s,2H),3.24(s,1H),3.19(s,1H),3.09(d,J=0.9Hz,3H),2 .75(s,1H),2.57–2.49(m,3H),2.32(s,3H),1.33(s,3H),1.28(s,5H).HRMS(ESI):m / z calcd.for C 32 H 33 F2N9O7,[M+H] + :694.2471,found:694.2469.
[0169] Example 33: Covalent Binding Study of Compounds to Bruton's Tyrosine Kinase (BTK)
[0170] 1. Experimental methods
[0171] The covalent binding of I1 and I3 to Bruton's tyrosine kinase (BTK) was determined by mass spectrometry. The target protein was diluted to 2 μM in buffer, and then 1 / 100-1 / 20 of the test compound was added from the 200 μM solution to obtain a 2 μM concentration of the test compound. The reaction mixture was injected into the LC / MS at different times at room temperature. For data analysis, the raw spectra were deconvoluted using a 20000:40000Da window and 1Da resolution. The labeling percentage of the compound is the labeling of the specific compound divided by the total protein detected.
[0172] 2. Experimental results
[0173] The results are as follows Figure 1 and Figure 2 As shown, the results show that the compound can achieve complete binding with BTK under the condition of incubation at room temperature for 1 hour, and the molecular weight calculation results are consistent with the addition-elimination NO release mechanism proposed in the compound design.
[0174] Example 34: NO release study of compounds
[0175] 1. Experimental methods
[0176] The NO release of the target compound was determined by Griess method in different pH buffer solutions, target protein storage solution, rat plasma, rat liver microsomes, etc. The NO fluorescent probe method was combined with flow cytometry to determine the NO release of the target compound in lymphoma Daudi cells.
[0177] 2. Experimental results
[0178] The results are as follows Figure 3 The NO release of I1 in BTK storage solution was significantly higher than that in rat liver microsomes, rat plasma and GSH solution, indicating that I1 has a higher release selectivity. The DAF-FM DA probe method was used to measure the NO release of I1 in cells. Compared with ibrutinib, it has a significant NO release in B cell lymphoma Daudi cells.
[0179] Example 35: Stability study of compounds
[0180] 1. Experimental methods
[0181] The LC-MS method was used to investigate the stability of compounds I1-I6 in plasma, liver microsomes and GSH media.
[0182] 2. Experimental results
[0183] The results are as follows Figure 4 , indicating that compounds I1-I6 all have high in vitro stability.
[0184] Example 36: In vitro kinase inhibitory activity study of compounds
[0185] 1. Experimental methods
[0186] The ADP-Glo method was used to determine the kinase activities of compounds I1-I6, II1-II6 and III1-III6 against BTK, HER2 and Fgfr4, respectively (IC 50 ). Add 50 μL of the test compound to the 384-well dilution plate, serially dilute the test compound 5 times in DMSO at a ratio of 1:3 in each column, transfer 0.025 μL of the diluted test compound solution in each row to the 384-well assay plate using Echo, add 2.5 μL of enzyme working solution to the 384-well assay plate, centrifuge at 1000 prm for 1 minute, add 2.5 μL of substrate (ATP and substrate) working solution to start the reaction, incubate at 25°C for 0, 2, 4, 8, 15, 30, 60, 90 minutes, add 5 μL of TK Beads solution to initiate the reaction, incubate at 25°C for 60 minutes, read the 665nm and 620nm fluorescence signals with BMG (ratio 665 / 620).
[0187] 2. Experimental results
[0188] The results are shown in Table 1, Table 2 and Table 3
[0189] Table 1. Results of the inhibitory activity of compounds I1-I6 on BTK kinase
[0190]
[0191] Table 2. Results of the inhibitory activity of compounds II1-II6 on HER2 kinase
[0192]
[0193] Table 3. Results of the inhibitory activity of compounds III1-III6 on Fgfr4 kinase
[0194]
[0195] Example 37: In vitro anti-tumor cell proliferation activity study of the compound
[0196] 1. Experimental methods
[0197] The inhibitory activity of compounds I1-I6, II1-II6 and III1-III6 on tumor cell lines was tested using the CCK8 method. The cell lines were cultured in DMEM medium or PRMI 1640 medium containing 10% fetal bovine serum (FBS) (SJSA-1 and A549 cells were cultured in PRMI 1640 medium, MDA-MB-231 and HeLa cells were cultured in DMEM medium). All cell lines were cultured in a Shellab 2323-2CO2 constant temperature cell culture incubator under the following conditions: air containing 5% CO2 at a temperature of 37°C. Cell activity was determined using the CCK8 (Beyotime) method. Cells were inoculated in a 96-well plate at a cell density of 8000-10000 / well. After incubation in a constant temperature incubator for 24 hours, the cells were observed under a microscope to be in good condition and almost completely adherent to the wall. Different concentrations of compounds or 0.1% DMSO were added and cultured for 48 hours. After 48 h, CCK8 reagent was added, and the culture was continued for two hours. The absorbance OD value of each well at a wavelength of 450 nM was measured using an Envision 2104 multifunctional microwell analyzer (Perkin Elmer). Finally, GraphPad 8.0 was used to fit the dose-effect curve and calculate the IC 50 Value. Cell survival rate = [(experimental group - blank control group) / (control group - blank control group)] * 100%. Experimental group: cells + CCK8 solution + drug solution; control group: cells + CCK8 solution + 0.1% DMSO; blank control group: no cells + CCK8 solution. Three parallel wells were set for each group, and each experiment was repeated three times.
[0198] 2. Experimental results
[0199] The results are shown in Tables 4, 5 and 6.
[0200] Table 4. In vitro antitumor activity test results of compounds I1-I8 (IC 50 , μM)
[0201]
[0202] Table 5. In vitro antitumor activity test results of compounds II1-II6
[0203]
[0204] Table 6. In vitro antitumor activity test results of compounds III1-III6
[0205]
[0206] Example 38: Binding study of compounds to kinases
[0207] 1. Experimental methods
[0208] The Kinact / ki parameter of I1 was tested using the HTRF / ADP-Glo / FI method. 50 μL of I1 was added to a 384-well dilution plate, and I1 was serially diluted 5 times in DMSO at a ratio of 1:3 in each column. 0.025 μL of diluted I1 solution was transferred to a 384-well assay plate using an Echo, 2.5 μL of enzyme working solution was added to the 384-well assay plate, centrifuged at 1000 prms for 1 minute, 2.5 μL of substrate (ATP and substrate) working solution was added to start the reaction, and incubated at 25°C for 0, 2, 4, 8, 15, 30, 60, and 90 minutes, respectively, and 5 μL of TK Beads solution was added to initiate the reaction, and incubated at 25°C for 60 minutes, and the fluorescence signals at 665 nm and 620 nm were read with BMG (ratio: 665 / 620).
[0209] 2. Experimental results
[0210] The results are as follows Figure 5 , indicating that the modification of the warhead site of I1 increased steric hindrance, making the first non-covalent binding step slower, but the modification of the warhead site did not significantly affect the binding efficacy of I1 and BTK.
[0211] Example 39: Kinase profiling study of compounds
[0212] 1. Experimental methods
[0213] Compound I1 was subjected to kinase profiling using the ADP-Glo Kinase Assay. 2× ATP and substrate solutions and 2× kinase and metal solutions were prepared using assay buffer and 20 nL of compound was transferred to a 384 assay plate via an Echo 655. 2 μL of 2× kinase and metal solution was added, mixed and incubated in a 384 assay plate at 25°C for 10 minutes. 2 μL of 2× substrate and ATP solution was added to the wells and incubated at 25°C for 60 minutes. 4 μL of ADP-Glo Reagent was added to the wells and incubated at 25°C for 40 minutes. 8 μL of Kinase Detection Reagent was added to the wells and incubated at 25°C for 40 minutes. Signals were recorded on a microtiter plate reader.
[0214] 2. Experimental results
[0215] The results are as follows Figure 6 , indicating that the modification of the warhead site has improved the kinase selectivity of compound I1, and compared with ibrutinib, it has effectively reduced off-target inhibition of JAK family kinases, ErbB family kinases, etc. This may make I1 have fewer gastrointestinal side effects than ibrutinib.
[0216] Example 40: In vivo activity study of compounds
[0217] 1. Experimental methods
[0218] 150 μL TMD8 cell suspension (6×10 6 cells) were subcutaneously inoculated into the right back of 8-week-old female BALB / c nude mice. When the average tumor volume reached about 60 mm 3 At 14:00, mice were randomly divided into a blank control group (n=8 / group) and a compound I1 group (15 mg / kg, PO, BID). Tumor volume and body weight were recorded every other day after administration. After 20 days, all mice were sacrificed and the tumors were retained for further study. The size of the tumor was calculated using the formula: V (tumor volume, mm 3 )=L(length, mm)×W2(width, mm)×0.5. The tumor growth inhibition rate (TGI) was calculated using the following formula: TGI=(1-TWt / TWc)×100%, where TWt and TWc represent the average tumor weights of the treatment group and the control group on the 20th day, respectively.
[0219] 2. Experimental results
[0220] The results are as follows Figure 7 Compared with the blank control group, the experimental group A12 (15 mg / kg) can significantly inhibit the growth of tumors. During the experiment, the mice were in good health, with normal activities, normal water and food intake, normal skin gloss and color, no diarrhea, and no inflammation at the tumor site.
[0221] Example 41: Co-localization study of NO release of compounds and Bruton's tyrosine kinase (BTK)
[0222] 1. Experimental methods
[0223] Construct a BTK-mCherry (excitation wavelength 587nm, emission wavelength 610nm) lentiviral vector with pKG-CMV-MCS-EF1-Puro as the carrier. Cultivate Daudi cells, transfect them with lentivirus for 48 hours, add DAF-FM DA (excitation wavelength 495nm, emission wavelength 515nm) and incubate for 15 minutes, discard and wash 3 times, wash off the excess dye, add compounds and incubate, so that the final concentration of the compounds is 1μM, 5μM, 10μM, etc.; incubate the compounds for 5min / 30min / 60min, etc.; after incubation, add PBS and wash 3 times; add 300μL of ready-to-use DAPI dye solution, incubate at room temperature and avoid light for 10min; wash 3 times with PBS. Smear, observe the cells under a focusing microscope, and observe the images at 600 times.
[0224] 2. Experimental results
[0225] The results are as follows Figure 8 The results showed that NO release and BTK had clear subcellular co-localization. Then, the NO scavenger PTIO was added, and confocal imaging showed that NO was scavenged and there was no NO at BTK. The above results show that I1 releases NO in situ and in a very small range at BTK in the cell.
[0226] Example 42: Study on the increase of nitrosylation and decrease of phosphorylation / inhibition of phosphorylation signal transduction of Bruton's tyrosine kinase (BTK) caused by NO release of compounds
[0227] 1. Experimental methods
[0228] Daudi cells were cultured, and the cell suspension was incubated with 1-10 μM of each group of compounds for 1-5 hours. DMSO group, ibrutinib group, I1 group, and azo group were set up. After Biotin-Switch conversion, Streptavidin Agarose (lifetechnologies, catalog number: SA100-04) was used for purification, and the nitrosation of the target protein was characterized. At the same time, the same group of cells was used to simultaneously evaluate the effect of nitrosylation on the phosphorylation degree of the target protein using WB, revealing the crosstalk mechanism between kinase nitrosylation and phosphorylation.
[0229] 2. Experimental results
[0230] The results are as follows Fig. 9 After incubation of the compound with Daudi cells, I1 caused a significant increase in BTK nitrosylation compared to ibrutinib, but did not cause a global increase in nitrosylation compared to azodiol salts (non-selective NO donors). At the same time, the effect of I1 on the phosphorylation of BTK and the kinase protein kinase B (AKT) that interacts with BTK was tested compared to ibrutinib. The results showed that I1 significantly reduced the phosphorylation of BTK and AKT compared to ibrutinib, indicating that the nitrosylation and covalent inhibition brought by NO played a synergistic role in inhibiting phosphorylation.
Claims
1. A covalent kinase inhibitor, characterized in that Having a structure of Formula I, II, III, IV or V, and also including pharmaceutically acceptable salts thereof, in: R1 and R2 are selected from C1-C4 alkyl or R1, R2 and the nitrogen to which they are attached together form a 4-7 membered heterocyclic ring containing 1-2 nitrogen, oxygen, or sulfur atoms, and the ring carbon atom is substituted by at least one hydrogen, hydroxyl, halogen, C1-C4 alkyl, halogen-substituted C1-C4 alkyl, or hydroxyl-substituted C1-C4 alkyl; The kinase inhibitor nucleus is selected from:
2. The covalent kinase inhibitor according to claim 1, characterized in that In the structure: R1 and R2 are selected from methyl, ethyl or R1, R2 and the N to which they are connected together form a 5-6 membered heterocyclic ring, wherein the heterocyclic ring is a morpholine ring, a piperidine ring, or a tetrahydropyrrole ring, and the ring carbon atom is substituted by at least one hydrogen, hydroxyl, fluorine, chlorine, bromine, methyl, ethyl, trifluoromethyl, hydroxymethyl, or hydroxyethyl.
3. The covalent kinase inhibitor according to claim 2, characterized in that In the structure: NR1R2 is selected from dimethylamino, methylethylamino, diethylamino, morpholinyl, tetrahydropyrrolyl, 2-hydroxymethyltetrahydropyrrolyl, piperidinyl, 4-hydroxypiperidinyl.
4. The covalent kinase inhibitor according to claim 1, characterized in that Select any of the following compounds:
5. The covalent kinase inhibitor according to claim 1, characterized in that The pharmaceutically acceptable salt is a salt of the kinase inhibitor formed with any of the following acids: hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, carbonic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, camphorsulfonic acid, citric acid, tartaric acid, malic acid, lactic acid, pyruvic acid, acetic acid, maleic acid, succinic acid, fumaric acid, salicylic acid, phenylacetic acid, ferulic acid or mandelic acid.
6. A method for preparing the covalent kinase inhibitor according to claim 1, characterized in that: The following steps are involved: (1) When the covalent kinase inhibitor has the structural formula of Formula I or II, (i) Compound 1 is reacted in the presence of paraformaldehyde, triethylenediamine and phenol to obtain intermediate 2; (ii) intermediate 2 is reacted in the presence of p-toluenesulfonyl chloride and triethylamine to obtain intermediate 3; (iii) intermediate 3 reacts with the corresponding azodiol salt or AgNO2 under the catalysis of 15-crown-5-ether to obtain the final product 4 or 5; (2) When the covalent kinase inhibitor has the structural formula III, (i) the kinase inhibitor core 6 is reacted with 2,3-dibromopropionic acid under the catalysis of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to obtain compound 7; (ii) Compound 7 reacts with nitromethane to obtain the final product 8; (3) When the covalent kinase inhibitor has the structural formula IV, (i) tert-butyl 3-oxocyclobutylcarboxylate is reacted in the presence of hydroxylamine hydrochloride and sodium acetate to obtain oxime intermediate 10; (ii) intermediate 10 reacts with urea peroxide and trifluoroacetic anhydride to obtain intermediate 11; (iii) intermediate 11 reacts with kinase inhibitor core 6 to obtain final product 12; (4) When the covalent kinase inhibitor has a structural formula of Formula V, the kinase inhibitor core 6 is reacted with 2-bromo-1-(3,3-dinitroazetidine-1-yl)ethanone to obtain the final product 13; Wherein, R1, R2, and the kinase inhibitor core are defined as in claim 1; The pharmaceutically acceptable salt is obtained by reacting the corresponding acid with the covalent kinase inhibitor prepared by the above method to form a salt.
7. A pharmaceutical composition, characterized in that The invention comprises the covalent kinase inhibitor according to claim 1 and a pharmaceutically acceptable carrier.
8. Use of the covalent kinase inhibitor according to claim 1 or the pharmaceutical composition according to claim 7 in the preparation of a drug for treating and / or preventing a proliferative disease, delaying the progression of a proliferative disease, alleviating the symptoms of a proliferative disease, assisting in the treatment of a proliferative disease, or managing a proliferative disease.
9. The use according to claim 8, characterized in that: The proliferative disease is selected from the group consisting of tumors, rheumatic diseases, chronic inflammation, and infectious mononucleosis.
10. The use according to claim 9, characterized in that: The proliferative disease is selected from the group consisting of gastric cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, prostate cancer, thyroid cancer, pancreatic cancer, bladder cancer, kidney cancer, brain tumor, cervical cancer, uterine cancer, ovarian cancer, cervical cancer, testicular tumor, myeloma, osteosarcoma, malignant glioma, myeloproliferative disease, malignant lymphoma, chronic lymphocytic leukemia, monocytic leukemia, hairy cell leukemia, acute lymphocytic leukemia, non-lymphoreticular tumor, solitary plasmacytoma, lymphoblastoma, Hodgkin's lymphoma, neuroblastoma, retinoblastoma, neuroendocrine cell tumor, pancreatic islet cell tumor, cell tumor, melanoma, atherosclerosis, pulmonary fibrosis, rheumatic diseases, chronic inflammation, papular mucinosis, familial splenic anemia, amyloidosis, heavy chain disease, light chain disease, semi-molecular disease, cryoglobulinemia, primary macroglobulinemia, primary macroglobulinemia purpura, secondary benign monoclonal gammopathy, osteolytic lesions, some non-Hodgkin's lymphomas, Sezary syndrome, infectious mononucleosis, acute histiocytosis, intestinal polyps, diverticulitis, colitis, pancreatitis, hepatitis, chronic hepatitis, cirrhosis, cholecystitis.
Citation Information
Patent Citations
Tyrosine kinase inhibitors
CN103534258A
Treatment of dry eye
US20150182530A1
